{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"89bio, Inc."},"Symbol":{"label":"Symbol","value":"ETNB"},"Address":{"label":"Address","value":"142 SANSOME STREET,SECOND FLOOR, SAN FRANCISCO, California, 94104, United States"},"Phone":{"label":"Phone","value":"+1 415 432-9270"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"89bio Inc a United States-based clinical-stage biopharmaceutical company focused on the development of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin is a long-acting glycopegylated fibroblast growth factor 21 (FGF21) analogue. The fibroblast growth factor 21 (FGF21) is developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG)."},"CompanyUrl":{"label":"Company Url","value":"https://www.89bio.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Francis Willard Sarena","title":"Chief Operating Officer"},{"name":"Harry H. Mansbach","title":"Chief Medical Officer"},{"name":"Paul Shin","title":"VP-Research & Development Operations"},{"name":"Quoc Le-Nguyen","title":"Chief Technical Operations Officer & Head-Quality"},{"name":"Rohan Palekar","title":"Chief Executive Officer & Director"},{"name":"Wenyan Wang","title":"Vice President-Clinical Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}